Merck Completes Women's Health Organon Spinoff

Comments
Loading...
  • In a move to free up a cash windfall and streamline the business, Merck & Co Inc MRK had long planned to slice away its women’s health business into a standalone spinoff.
  • As of Thursday, that spinoff, dubbed Organon, is now a public entity all its own. Organon & Co. OGN debuted on the NYSE.
  • As a part of the spinoff, Merck will receive a $9 billion special tax-free dividend that it will use for a future acquisition.
  • Organon is focused on Nexplanon, a long-active reversible contraceptive that has a patent expiring in 2027.
  • Last year, its sales were around $680 million. The company said it could boost sales to more than $1 billion in 2021.
  • Price Action: MRK shares are down 3.3% at $73.36, while OGN is down 4.6% at $33.63 during the market session on the last check Thursday.
MRK Logo
MRKMerck & Co Inc
$94.05-0.70%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum22.72
Growth97.84
Quality77.25
Value13.81
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In: